35th week of 2013 patent applcation highlights part 47 |
Patent application number | Title | Published |
20130224184 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 2013-08-29 |
20130224185 | PROTEIN FORMULATION - A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein. | 2013-08-29 |
20130224186 | OXAZOLE AND THIAZOLE COMPOUNDS AS KSP INHIBITORS - Disclosed are new substituted oxazole and thiazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: | 2013-08-29 |
20130224187 | ANTI-C5a ANTIBODIES AND METHODS FOR USING THE ANTIBODIES - The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease. | 2013-08-29 |
20130224188 | CD47 Antibodies and Methods of Use Thereof - This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics. | 2013-08-29 |
20130224189 | TWEAK RECEPTOR - The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue. | 2013-08-29 |
20130224190 | ANTI-CD19 ANTIBODY HAVING ADCC AND CDC FUNCTIONS AND IMPROVED GLYCOSYLATION PROFILE - The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease. | 2013-08-29 |
20130224191 | NOTUM PROTEIN MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided. | 2013-08-29 |
20130224192 | METHOD FOR THE PROGNOSIS OF THE PROGRESSION OF CANCER - The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a cancer, in particular with a breast cancer, a lung cancer or other primary cancer, said methods comprising the step of detecting a higher expression level of FERMT1 gene in a tumour sample compared to a control reference values. The invention further relates to inhibitors of FERMT1 expression and their uses in the treatment of cancer or metastasis. | 2013-08-29 |
20130224193 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 2013-08-29 |
20130224194 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 2013-08-29 |
20130224195 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE - New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. | 2013-08-29 |
20130224196 | METHODS AND COMPOSITIONS USING KLOTO-FGF FUSION POLYPEPTIDES - The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | 2013-08-29 |
20130224197 | Methods for treatment of brain injury utilizing biologics - A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included. | 2013-08-29 |
20130224198 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo compared to naturally occurring or recombinant native human erythropoietin. In one embodiment, the protein has a half-life in vivo at least three-fold higher than native human erythropoietin. The fusion protein exhibits enhanced erythropoietic bioactivity compared to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human IgG1, which Fc fragment includes the hinge region, CH2 and CH3 domains. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen risk of an immunogenic response when administered. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. | 2013-08-29 |
20130224199 | VIRAL CHEMOKINE-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. | 2013-08-29 |
20130224200 | Product and Process for Inhibition of Biofilm Development - Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions. | 2013-08-29 |
20130224201 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. | 2013-08-29 |
20130224202 | SINGLE-CHAIN VARIABLE FRAGMENT ANTI-CD133 ANTIBODIES AND USES THEREOF - Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133. | 2013-08-29 |
20130224203 | Pharmaceutical Composition of Recombinant Polyclonal Immunoglobulins - There is disclosed a recombinant pharmaceutical composition comprising a large plurality of recombinant immunoglobulins made by expression of a wide diversity of antibodies from a recombinant antibody library, preferably obtained from a wide diversity of human sources, synthetic or semi-synthetic germline immunoglobulin sequences, or a combination thereof, and then purified. Mammalian cell expression antibody libraries normally produce antibodies with significant diversity or different antibodies that bind to different targets. There is further disclosed a recombinant pharmaceutical composition made from a mammalian expression library configured to excrete, rather than display their antibodies on the cell surface, and then purified to form the pharmaceutical composition from the excreted antibodies. | 2013-08-29 |
20130224204 | Method of Treatment Based on ATAD2 Inhibitors - A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of the bromodomain-containing protein: ATAD2. | 2013-08-29 |
20130224205 | MULTISPECIFIC DEIMMUNIZED CD3-BINDERS - The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention. | 2013-08-29 |
20130224206 | COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY - This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits. | 2013-08-29 |
20130224207 | IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE - Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses. | 2013-08-29 |
20130224208 | GLIOMA TREATMENT METHOD, GLIOMA TESTING METHOD, METHOD FOR DELIVERING DESIRED SUBSTANCE TO GLIOMA, AND DRUGS USED IN THESE METHODS - An object is to provide glioma treatment and testing methods, and a method for delivering a desired substance to a glioma, all of which target a molecule specifically expressed in a glioma, as well as drugs and so forth used in these methods. It has been found out that targeting Eva1 or Ceacam1 enables glioma treatment and testing, and delivering of a desired substance to a glioma. | 2013-08-29 |
20130224209 | METHODS FOR DIAGNOSING AND TREATING PROSTATE AND LUNG CANCER - Methods for detecting and treating prostate and lung cancer are disclosed In practicing the method, a subject sample is assayed for GPR110 protein or its RNA transcript, and the GPR110 or transcript level observed is used in determining whether the subject has an elevated GPR110 level associated with prostate or lung cancer. Patients with such elevated levels may be treated, in accordance with the invention, with a variety of GPR110 related immunotherapy agents. | 2013-08-29 |
20130224210 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 2013-08-29 |
20130224211 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF - The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments. | 2013-08-29 |
20130224212 | METHODS AND PRODUCTS RELATING TO GSK3SS REGULATION - The invention relates to methods and compositions for regulation of GSK3β activity. The invention provides phosphorylated GSK3β polypeptides and antibodies that recognize such polypeptides. The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3β activity. | 2013-08-29 |
20130224213 | Compositions and Methods for Stabilizing Protein-Containing Formulations - The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof. | 2013-08-29 |
20130224214 | Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis - The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions. | 2013-08-29 |
20130224215 | A B Cell Depleting Agent for the Treatment of Atherosclerosis - The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis. | 2013-08-29 |
20130224216 | ANTI-LPS ENRICHED IMMUNOGLOBULIN FOR USE IN TREATMENT AND/OR PROPHYLAXIS OF A PATHOLOGIC DISORDER - Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. | 2013-08-29 |
20130224217 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION - The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 2013-08-29 |
20130224218 | Methods and Compositions for the Inhibition of Fructokinase - The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease. | 2013-08-29 |
20130224219 | DRUG AND METHOD FOR THE PROPHYLAXIS OF HIV INFECTION AND FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES CAUSED BY OR ASSOCIATED WITH HIV, INCLUDING AIDS - The drug for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, comprises an activated, potentiated form of antibodies to a protein or peptide of the immune system which interacts with the HIV or has a content and/or functional activity which changes in connection with an HIV infection. Furthermore, in the method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, use is made of an activated, potentiated form of antibodies to an antigen, namely a protein or peptide of the immune system, which interacts with the HIV or has a content and/or functional activity which changes in connection with an HIV infection | 2013-08-29 |
20130224220 | ErbB3 BINDING ANTIBODY - The present invention relates to an antibody, particularly a monoclonal antibody, which binds to the ErbB3 receptor, compositions comprising such an antibody as well as methods using such an antibody. | 2013-08-29 |
20130224221 | BIOMARKERS FOR SCHIZOPHRENIA - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. | 2013-08-29 |
20130224222 | METHODS AND ASSAYS FOR TREATING OR PREVENTING OBESITY AND/OR DIABETES OR INCREASING INSULIN SENSITIVITY - The present invention provides methods for determining a putative agent that treats or prevents obesity and/or diabetes or increasing insulin sensitivity, the method comprising contacting cells with the putative agent and measuring thioredoxin-interacting protein (TXNIP) or thioredoxin expression or activity in the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of preventing or treating obesity and/or diabetes or of increasing insulin sensitivity or glucose sensitivity, the method comprising administration of the agent that decreases the expression of TXNIP or activity of TXNIP. | 2013-08-29 |
20130224223 | Compositions and Methods for Treating Neurological Disorders - Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject. | 2013-08-29 |
20130224224 | CX3CR1-BINDING POLYPEPTIDES - The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes. | 2013-08-29 |
20130224225 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12. | 2013-08-29 |
20130224226 | INSECT BINDING ANTIBODIES - Described is a binding domain, preferably an antigen binding domain, more preferably an antigen binding domain that specifically binds a binding site on an insect. More specifically, described are antigen binding domains comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions, whereby the antigen binding domains are capable to bind specifically to an insect as a whole, preferably to a binding site on the insect surface. Further described is the use of the binding domain to deliver a compound, preferably a biologically active agent to the insect, and to insecticidal compositions comprising the binding domain. | 2013-08-29 |
20130224227 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS - This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor. | 2013-08-29 |
20130224228 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods - Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers. | 2013-08-29 |
20130224229 | Novel Curcumin-Antibody Conjugates as Anti-Cancer Agents - The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H | 2013-08-29 |
20130224230 | THERAPEUTIC USES OF GLANDULAR KALLIKREIN - The present invention relates to pharmaceutical compositions comprising glandular kallikrein in combination with myelin basic protein or copaxone for use in the treatment of multiple sclerosis. The present invention further relates to a method of suppressing autoimmune responses in a patient afflicted with or suffering at least one clinical sign of multiple sclerosis, comprising administering to said patient a therapeutically effective amount of glandular kallikrein in combination with a therapeutically effective amount of myelin basic protein or copaxone. | 2013-08-29 |
20130224231 | NOVEL PEPTIDES FOR TREATING AND PREVENTING IMMUNE-RELATED DISORDERS, INCLUDING TREATING AND PREVENTING INFECTION BY MODULATING INNATE IMMUNITY - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 2013-08-29 |
20130224232 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF - There are provided compounds of formula I wherein k, m, n, p, R, R′, R″, R′″, R3 and R4 are as defined in the application. Other embodiments are also disclosed. | 2013-08-29 |
20130224233 | IMMUNOTHERAPEUTIC METHOD FOR TREATING PROSTATE CANCER - The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment of prostate cancer. Said immunogenic polypeptides are provided by the zona pellucida (ZP) (glyco)proteins. ZP (glyco)proteins and fragments thereof that can induce a CD8 | 2013-08-29 |
20130224234 | TTLL4 PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTLL4 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from TTLL4 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTLL4, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention. | 2013-08-29 |
20130224235 | POTATO VIRUS A COAT PROTEIN-BASED VACCINES FOR MELANOMA - A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein and DNA vaccines, based on potato virus A coat protein. | 2013-08-29 |
20130224236 | HSV-1 EPITOPES AND METHODS FOR USING SAME - The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2013-08-29 |
20130224237 | INHIBITION OF NONSENSE MEDIATED DECAY PATHWAYS - Compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the treatment of many diseases. | 2013-08-29 |
20130224238 | GPCR AS VACCINES OR FOR REMOVING/INHIBITING AUTOANTIBODIES, TOXINS OR LIGANDS BINDING TO THE GPCR - There is provided a G protein coupled receptor (GPCR) or a polynucleotide encoding said GPCR for use as a vaccine. There is also provided methods of antagonising or agonising A GPCR in vivo comprising the administration of a GPCR or a polynucleotide encoding a GPCR to a subject. The invention further provides a GPCR for use in inhibiting an activity of a GPCR binding partner in a subject. | 2013-08-29 |
20130224239 | ALCOHOLIC EXTRACT OF FUNGI OF GENUS CUNNINGHAMELLA AND USE THEREOF - The present invention relates to an alcoholic extract of fungi of the genus | 2013-08-29 |
20130224240 | METHOD OF REDUCING WEIGHT USING COMPOSITION CONTAINING FUCOXANTHIN EXTRACT - A method of reducing a weight of a subject includes administering to the subject in need thereof a composition comprised of fucoxanthin extract and at least one selected from the group consisting of tocotrienol, fucoidan and a combination thereof, wherein the subject is a mammal. | 2013-08-29 |
20130224241 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 2013-08-29 |
20130224242 | Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 2013-08-29 |
20130224243 | USE OF HERPES VECTORS FOR TUMOR THERAPY - Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator. | 2013-08-29 |
20130224244 | VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE (CIRD) - A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against | 2013-08-29 |
20130224245 | CONCENTRATION OF VACCINE ANTIGENS WITHOUT LYOPHILIZATION - An antigen concentration procedure does not involve lyophilisation of a bulk antigen before its final formulation and/or delivery. Thus a process for preparing a vaccine comprises steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen, to provide a concentrated antigen, and (ii) formulating a vaccine from the concentrated antigen. The concentrated antigen is not lyophilised between or during steps (i) and (ii). The invention is particularly useful for preparing solid vaccine forms. | 2013-08-29 |
20130224246 | MODIFIED HEPATITIS C VIRUS PROTEINS - A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597. | 2013-08-29 |
20130224247 | VACCINE AGAINST EHRLICHIA CANIS - Vaccine and/or immunogenic compositions that comprise an effective immunizing amount of an | 2013-08-29 |
20130224248 | FORMULATION SUITABLE FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENTS - A formulation free of protein which stabilizes pharmaceutical active proteins, peptides, or mixtures thereof in large scale production processes comprising a mixture of a hydrophilic polymer and a non-ionic detergent, and a mixture of a polyalcohol and a sugar. In some embodiments the polyalcohol is absent. | 2013-08-29 |
20130224249 | RECOMBINANT TRYPANOSOMA CRUZI CELLS USEFUL AS ANTI-CANCER IMMUNE AGENTS - Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is | 2013-08-29 |
20130224250 | Purified Plasmodium and Vaccine Composition - Disclosed are substantially purified | 2013-08-29 |
20130224251 | VARIANTS OF GROUP 6 ALLERGENS OF THE TRUE GRASSES HAVING REDUCED ALLERGENEITY DUE TO MUTAGENESIS OF PROLINE RESIDUES - The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes. | 2013-08-29 |
20130224252 | INTESTINE IMMUNOMODULATOR - The purpose of the present invention is to provide a better intestine immunomodulator. The intestine immunomodulator of the present invention comprises bacterial cells or a bacterial component of a | 2013-08-29 |
20130224253 | NON-REPLICATING PROBIOTIC MICRO-ORGANISMS PROTECT AGAINST UPPER RESPIRATORY TRACT INFECTIONS - The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections. | 2013-08-29 |
20130224254 | NON-REPLICATING PROBIOTIC MICRO-ORGANISMS PROTECT CHILDREN AGAINST GASTROINTESTINAL INFECTIONS - The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from gastro-intestinal infections, in particular diarrhea. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of gastrointestinal infections in children. | 2013-08-29 |
20130224255 | Treatment Of Diabetic Patients With A Drug Eluting Stent And Adjunctive Therapy - Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease in diabetic patients. The methods include both implantation of a stent including a first drug. Some embodiments include additional therapy, such as the co-administration of another drug. Some embodiments involve different stent selection for a diabetic patient compared to a non-diabetic patient. | 2013-08-29 |
20130224256 | HYDROGEL NANOCOMPOSITE WOUND DRESSING AND A METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide hydrogel nanocomposite wound dressing comprising a polymeric basal matrix, a reinforcing agent, a biological sensor and an antibiotic for a slow release in a wound when applied. The polymeric basal matrix is made up of polyvinyl alcohol polymer with an amount of 1-15% by weight. The reinforcing agent comprises clay nanoparticles to inhibit a sudden drug release. The clay nanoparticles comprise montmorillonite nano particles with an amount of 0-2% by weight. The biological sensor is a peptide chain. The peptide chain is thrombin sensitive with an amount from 50 to 200 mg. The antibiotic is gentamycine with an amount of 1-3% by weight. The embodiments herein also provide a method of synthesizing the hydrogel nanocomposite wound dressing. | 2013-08-29 |
20130224257 | METHOD FOR PREPARING MICROSPHERES AND MICROSPHERES PRODUCED THEREBY - The present invention relates to a method for preparing microsphere and microspheres produced thereby. The method comprises: mixing a water-insoluble organic solvent with a dispersion solvent; mixing a polymer compound, a drug and a water-insoluble organic solvent to prepare a dispersed phase; mixing the dispersed phase with the dispersion solvent mixed with the water-insoluble organic solvent to prepare an emulsion; and adding a base or an acid to the prepared emulsion. With the method, it is possible to prepare a drug-containing polymeric microsphere cost-effectively and conveniently. | 2013-08-29 |
20130224258 | BISMUTH-THIOLS AS ANTISEPTICS FOR AGRICULTURAL, INDUSTRIAL AND OTHER USES - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections. | 2013-08-29 |
20130224259 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof - The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X. | 2013-08-29 |
20130224260 | TISSUE SCAFFOLDS DERIVED FROM FORESTOMACH EXTRACELLULAR MATRIX - The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold. | 2013-08-29 |
20130224261 | ENVIRONMENTALLY-RESPONSIVE NANOCOMPOSITES AND METHODS OF THEIR USE - Environmentally-responsive composites useful for intracellular delivery of therapeutic agents. | 2013-08-29 |
20130224262 | TRANSDERMAL PREPARATION - The invention provides a transdermal absorption preparation showing sufficient adhesiveness on adhesion to the skin, causing low skin irritation, and capable of well controlling releaseability of lidocaine. The transdermal absorption preparation contains a support and an adhesive layer formed on the support. The adhesive layer contains a drug, as well as a thermoplastic elastomer, more than 300 parts by weight of liquid paraffin per 100 parts by weight of the elastomer, not more than 10 wt % of a tackifier, lidocaine, and an organic acid. | 2013-08-29 |
20130224263 | CALCIUM PHOSPHATE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A calcium phosphate composition comprising calcium phosphate particles (A) and a sulfonic acid salt (B), wherein the calcium phosphate composition contains 0.5 to 20 parts by weight of the sulfonic acid salt (B) based on 100 parts by weight of the calcium phosphate particles (A). This provides a calcium phosphate composition that has a time between the addition of a liquid agent to the calcium phosphate composition and the completion of setting in the use at a clinical site and the like, i.e., a setting time which is within an appropriate range and that is high in mechanical strength and good in marginal sealing ability. | 2013-08-29 |
20130224264 | HIGH-LOADING, CONTROLLED-RELEASE MAGNESIUM ORAL DOSAGE FORMS AND METHODS FOR MAKING AND USING SAME - Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. | 2013-08-29 |
20130224265 | Dosage Forms for Tamper Prone Therapeutic Agents - A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form. | 2013-08-29 |
20130224266 | IMMUNOGENIC COMPOSITION - The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a | 2013-08-29 |
20130224267 | EMULSION CONTAINING ORGANOSILICON-BASED PORTIONS OF HOLLOW SPHERES - The present invention relates to a composition in the form of an emulsion containing portions of hollow spheres of organosilicon-based material, the portions of hollow spheres having a mean diameter ranging from 0.05 to 10 μm. The invention also relates to physiologically acceptable emulsion compositions comprising hollow spheres, and to a process for fading out skin surface defects, in particular to reduce the sheen of the skin and/or to fade out pores, shadows under the eyes, marks, wrinkles and/or fine lines, comprising the topical application to the skin of the above-mentioned compositions. | 2013-08-29 |
20130224268 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME - The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising topically administering to the subject in need thereof a hormonal nano formulation. | 2013-08-29 |
20130224269 | Biofunctional Anchored Extended-Wear Cosmetics - An extended wear cosmetic composition for application to a keratinous surface comprising a cosmetic particle coated with a biofunctional polymer wherein said coated particle adheres to the keratinous surface for an extended time period. A delivery system for conjugating a biofunctional polymer and cosmetic particle to specific cells on a keratinous surface such that the particle adheres to the keratinous surface for an extended time period. | 2013-08-29 |
20130224270 | Oral Care Composition Comprising Arginine and Calcium Carbonate - This invention relates to oral care compositions comprising a basic amino acid or salt thereof, and an abrasive system comprising natural calcium carbonate and precipitated calcium carbonate; and to methods of using and of making these compositions. | 2013-08-29 |
20130224271 | Oral Compositions Containing Microaggregates - The invention relates to a composite and oral care compositions for use in the mouth to retard the accumulation of dental plaque and/or calculus. The composite is a microaggregate comprising polymer coated, surfactant stabilized particles of a substantially insoluble metal, metal salt or metal oxide, for example zinc oxide. Also methods for retarding the accumulation of dental plaque and/or calculus are provided. | 2013-08-29 |
20130224272 | COMPOSITIONS AND METHODS FOR TREATING DEMODEX INFESTATIONS - Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular | 2013-08-29 |
20130224273 | TOPICAL SANITIZER AND METHOD OF USE WITH GLOVES - Topical sanitizer includes avenanthramides, which is an active component of oats that is beneficial to the skin. The topical sanitizer is used preferably in conjunction with gloves that have an inner coating that includes avenanthramides. By using topical sanitizer that includes avenanthramides before and after wearing gloves, the skin of the person wearing the glove is more exposed to the beneficial avenanthramides all during the workday, not just when wearing gloves. The result is healthier, much softer and more comfortable skin on the hands. | 2013-08-29 |
20130224274 | ANTIBACTERIAL MEDICINAL PRODUCT AND METHOD FOR PRODUCING SAME - The present invention relates to a medical product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at %. | 2013-08-29 |
20130224275 | DELIVERY OF COMPOSITIONS TO ARTHROPODS - A method of delivering a biologically active chemical agent to an arthropod pest of a bee, comprising exposing a surface of the said bee to carnauba wax particles having a volume mean diameter of at least 10 μm comprising at least one biologically active chemical agent, wherein the bee delivers the biologically active chemical agent to the arthropod pest, characterized in that the carnauba wax particles consist essentially of 89.5-99.4% by weight of carnauba wax; ≦10% by weight of biologically active chemical agent; and 0.5% by weight of flow agent. | 2013-08-29 |
20130224276 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant. | 2013-08-29 |
20130224277 | POROUS POLYSACCHARIDE SCAFFOLD COMPRISING NANO-HYDROXYAPATITE AND USE FOR BONE FORMATION - The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stem cells or growth factors. | 2013-08-29 |
20130224278 | RESORBABLE CELLULOSE BASED BIOMATERIAL AND IMPLANT - The present disclosure describes an implant for tissue replacement or augmentation including a resorbable non-pyrogenic porous body of irradiated oxidized cellulose, formed from a precurosr reactive mixture of irradiated cellulose and an oxidizing agent, where the body forms a heterogeneous three-dimensional fibrillar network. Also disclosed is a method for producing a body of oxidized cellulose including irradiating a body of cellulose to form an irradiated body of cellulose, and reacting the irradiated body of cellulose with an oxidizing agent to form a non-pyrogenic porous and resorbable body of oxidized cellulose. | 2013-08-29 |
20130224279 | PROCESS FOR THE PREPARATION OF CALCIUM SALT SUSPENSIONS - The current invention is related to a novel process for the production of aqueous suspensions of micro and nanoparticles of calcium salts smaller than 10 μm particle size, along with a method to enrich nutritional, nutraceutical, and pharmaceutical beverages with calcium salts. In the process, an aqueous suspension of calcium salt is subjected to pressurization with critical, subcritical, or supercritical carbon dioxide to increase the solubility of the calcium salt, which has a particle size greater than 30 μm. The resulting solution is expanded through a nozzle to generate a calcium salt suspension of micro and nanoparticles that is imperceptible to sight and taste. | 2013-08-29 |
20130224280 | TRANSDERMAL COMPOSITIONS AND METHODS FOR TREATING STRETCH MARKS - A transdermal delivery device for treating or preventing scars, such as stretch marks, comprising a composition comprising vitamin E, hyaluronan, biotin, | 2013-08-29 |
20130224281 | METHOD AND COMPOSITION FOR AMELIORATING THE EFFECTS FOR A SUBJECT EXPOSED TO RADIATION OR OTHER SOURCES OF OXIDATIVE STRESS - Radiation-oxidative exposure treatment compositions may include a mixture of micronutrient multivitamin and trace elements, a mixture of antioxidants and chemopreventative agents, and optionally a mixture of fatty acids. Methods of treatment of a subject exposed to a radiation source or an oxidative stress with the radiation-oxidative exposure treatment composition may include the step of administering to the subject a daily dose of the radiation-oxidative exposure treatment composition such that the life shortening effects induced by the radiation source or the oxidative stress are ameliorated. | 2013-08-29 |
20130224282 | Multistage Nanoparticles - Multistage nanostructures, e.g., for delivery of agents such as imaging agents and therapeutic agents to tumor vasculature. | 2013-08-29 |
20130224283 | BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY - A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks. | 2013-08-29 |